

Tarek Magdy

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4689078/publications.pdf>

Version: 2024-02-01

18
papers

720
citations

840776

11
h-index

996975

15
g-index

19
all docs

19
docs citations

19
times ranked

1252
citing authors

#	ARTICLE	IF	CITATIONS
1	PepFect 14, a novel cell-penetrating peptide for oligonucleotide delivery in solution and as solid formulation. <i>Nucleic Acids Research</i> , 2011, 39, 5284-5298.	14.5	199
2	Human Induced Pluripotent Stem Cell (hiPSC)-Derived Cells to Assess Drug Cardiotoxicity: Opportunities and Problems. <i>Annual Review of Pharmacology and Toxicology</i> , 2018, 58, 83-103.	9.4	89
3	Negligible-Cost and Weekend-Free Chemically Defined Human iPSC Culture. <i>Stem Cell Reports</i> , 2020, 14, 256-270.	4.8	80
4	Validating the pharmacogenomics of chemotherapy-induced cardiotoxicity: What is missing?. , 2016, 168, 113-125.		61
5	Solid formulation of cell-penetrating peptide nanocomplexes with siRNA and their stability in simulated gastric conditions. <i>Journal of Controlled Release</i> , 2012, 162, 1-8.	9.9	51
6	Identification of Drug Transporter Genomic Variants and Inhibitors That Protect Against Doxorubicin-Induced Cardiotoxicity. <i>Circulation</i> , 2022, 145, 279-294.	1.6	46
7	Role of ABC Transporters in Fluoropyrimidine-Based Chemotherapy Response. <i>Advances in Cancer Research</i> , 2015, 125, 217-243.	5.0	43
8	RARG variant predictive of doxorubicin-induced cardiotoxicity identifies a cardioprotective therapy. <i>Cell Stem Cell</i> , 2021, 28, 2076-2089.e7.	11.1	36
9	Targeting OCT3 attenuates doxorubicin-induced cardiac injury. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	7.1	33
10	Association of <i>GSTM1</i> null variant with anthracycline-related cardiomyopathy after childhood cancer—A Children's Oncology Group ALTE03N1 report. <i>Cancer</i> , 2020, 126, 4051-4058.	4.1	23
11	<i>ABCC11</i> / <i>MRP8</i> polymorphisms affect 5-fluorouracil-induced severe toxicity and hepatic expression. <i>Pharmacogenomics</i> , 2013, 14, 1433-1448.	1.3	21
12	Human In Vitro Models for Assessing the Genomic Basis of Chemotherapy-Induced Cardiovascular Toxicity. <i>Journal of Cardiovascular Translational Research</i> , 2020, 13, 377-389.	2.4	11
13	The future role of pharmacogenomics in anticancer agent-induced cardiovascular toxicity. <i>Pharmacogenomics</i> , 2018, 19, 79-82.	1.3	10
14	Precise and Cost-Effective Nanopore Sequencing for Post-GWAS Fine-Mapping and Causal Variant Identification. <i>iScience</i> , 2020, 23, 100971.	4.1	7
15	Unraveling Difficult Answers: From Genotype to Phenotype in Coronary Artery Disease. <i>Cell Stem Cell</i> , 2019, 24, 203-205.	11.1	5
16	Use of hiPSC to explicate genomic predisposition to anthracycline-induced cardiotoxicity. <i>Pharmacogenomics</i> , 2021, 22, 41-54.	1.3	4
17	A novel association between <i>GSTM1</i> null variant and anthracycline-induced cardiac dysfunction (ACD) in childhood cancer survivors (CCS): A COG ALTE03N1 report.. <i>Journal of Clinical Oncology</i> , 2019, 37, 10030-10030.	1.6	0
18	Prime time for doxorubicin-induced cardiotoxicity genetic testing. <i>Pharmacogenomics</i> , 2022, 23, 335-338.	1.3	0